Skip to main content
Premium Trial:

Request an Annual Quote

Erasmus University Medical Center to Use Spotfire DecisionSite

NEW YORK, Oct. 25 (GenomeWeb News) - The Erasmus University Medical Center, based in Rotterdam, The Netherlands, said today that it has entered into a three-year bioinformatics collaboration with Spotfire.

 

Under the terms of the agreement, Spotfire's DecisionSite analytics software will be available to researchers and students at the medical center.

 

Erasmus MC and Spotfire said they plan to collaborate on the development of analytic tools for biomarker identification and pathway visualization, and will work together to integrate DecisionSite with other data sources, such as Ensembl from the European Bioinformatics Institute.

 

The organizations also intend to jointly "investigate the deployment of visualization methods in clinical research & diagnostics - especially where visual analytics can be used for personalized treatment of patients."

 

Financial terms of the agreement were not provided.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.